D&D Pharmatech Inc
Company Profile
Business description
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.
Contact
4th floor, 24, Pangyo-ro 255beon-gil
Bundang-gu, Gyeonggi-do
Sampyeong-dong, I&C Building
Seongnam-si
KORT: +82 3180197771
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 6,846.37 | 428.58 | -5.89% |
| DAX 40 | 19,454.22 | 1,187.50 | -5.75% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 7,693.00 | 361.98 | -4.49% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |